Full-Time
Data Entry Associate
Quality Assurance
Updated on 9/3/2026
Harrow
201-500 employees
Compounds ophthalmic formulations; markets branded drugs
No salary listed
Remote in USA
Remote
Occasional travel up to 10% is expected; must be able to travel independently.
Bachelor's, Associate's
 Clerical & Data Entry (2) |
|---|
| , |
Get referred to Harrow
See people who can refer or advise you
- High school diploma or GED is preferred; an associate’s degree or relevant coursework is a plus.
- One to two years of experience in customer service or a call center environment is preferred.
- Strong verbal and written communication skills in English are required.
- Ability to manage confidential information with discretion.
- Proficiency in Microsoft Office is preferred, along with the ability to learn Quality Assurance systems.
- Ability to remain detail-oriented and organized and follow procedures accurately.
- Willingness to grow knowledge of pharmacovigilance principles and compliance expectations.
- Handle incoming Quality Assurance-related inquiries via email and phone, documenting and routing them as appropriate.
- Initiate and document Product Quality Complaints using standard forms and processes.
- Maintain and update the Product Quality Complaint tracker, including complaint status, actions taken, and closure updates.
- Perform routine updates to SharePoint folders, Quality Assurance trackers, and related documentation logs.
- Assist with document control tasks such as uploading, version control, and archiving of Quality Assurance files.
- Retrieve, file, and organize Quality Assurance documents upon request.
- Provide general administrative support to the Quality Assurance team as required.
- Perform additional tasks assigned by the Supervisor.
- High school diploma or GED.
- One to two years of experience in customer service or a call center environment.
- Proficiency in Microsoft Office.
Harrow focuses on eyecare pharmaceuticals, combining a compounding business (ImprimisRx) with a portfolio of FDA-approved branded drugs and biosimilars, plus biotech investments. Its products include customized compounded sterile and topical eye medications delivered directly to physicians and patients, alongside branded drugs acquired from other companies. The company differentiates itself by integrating a direct-to-physician compounding platform with an expanding branded drug portfolio, biosimilars, and owned production and distribution facilities across all 50 states. Its goal is to provide accessible, high-quality eye medications and grow its commercial and biotech assets to serve surgeons, hospitals, and patients nationwide.
Company Size
201-500
Company Stage
IPO
Headquarters
Nashville, Tennessee
Founded
1998
Get referred to Harrow
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue rose 11% to $70.7 million, with first-half revenue hitting $115 million.
- BYOOVIZ launched July 1, 2026; VERKAZIA relaunched June 10, 2026; IHEEZO pricing improved July 1.
- TYRVAYA acquisition announced August 6, 2026 adds more than $30 million in 2027 revenue.
What critics are saying
- First-half 2026 revenue reached $115 million, forcing a brutal $235 million-$250 million second-half ramp.
- Harrow carries $300 million of 8.625% notes due 2030 and $11.8 million H1 interest.
- ImprimisRx surrendered California compounding licenses on February 1, 2026, shrinking the compounding franchise.
What makes Harrow unique
- Harrow combines VEVYE, IHEEZO, TRIESENCE, BYOOVIZ, and TYRVAYA across dry eye and retina.
- Mark Baum pairs direct ophthalmology selling with acquisition-driven portfolio expansion, including Samsung Bioepis.
- August 1, 2026 VEVYE formulary expansion broadened access through a top-three national PBM.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Growth & Insights and Company News
6 month growth
↑ 25%1 year growth
↑ 25%2 year growth
↑ 25%Harrow reported first-half 2026 revenue of around $115 million, below expectations due to VEVYE pricing changes. The company maintained full-year guidance of $350 million to $365 million, requiring $235 million to $250 million in second-half revenue. IHEEZO delivered record quarterly demand of 65,477 units despite losing pass-through reimbursement, whilst ordering accounts grew 32% year-over-year. VEVYE prescriptions increased 21% sequentially, outpacing the 14% broader market growth, with market share rising to 14.6%. TRIESENCE demand surged 162% year-over-year to 14,529 units. However, adjusted EBITDA remained negative at $1.2 million. The pending TYRVAYA acquisition adds $20 million in annual costs. Hedge fund ownership declined from 24 to 22 funds, whilst short interest stands at 20.14% of float.
Harrow reported second-quarter revenue of $70.7 million, up 11% year-over-year, driven by stronger demand for VEVYE, IHEEZO and specialty products. The ophthalmic pharmaceutical company reiterated full-year revenue guidance of $350 million to $365 million and adjusted EBITDA guidance of $80 million to $100 million. VEVYE generated $29.4 million in quarterly revenue, up nearly 58% year-over-year, whilst IHEEZO contributed $15.6 million. Management expects second-half growth from improved VEVYE pricing, IHEEZO's 25% net price increase, and the BYOOVIZ and VERKAZIA launches. Harrow plans to acquire global rights to TYRVAYA for $30 million in cash, expecting more than $30 million of revenue in 2027 if the deal closes. The company also advanced pipeline programmes G-MELT and YOCHIL, targeting FDA submissions in 2027.
Harrow has announced the commercial launch of BYOOVIZ (ranibizumab-nuna) in the United States, an FDA-approved biosimilar referencing LUCENTIS. The launch follows Harrow's exclusive US commercialisation agreement with Samsung Bioepis, which also includes rights to OPUVIZ (aflibercept-yszy), another ophthalmology biosimilar. BYOOVIZ is approved for treating Neovascular Age-Related Macular Degeneration, Macular Edema following Retinal Vein Occlusion, and Myopic Choroidal Neovascularization. It was designated by the FDA as the first interchangeable ophthalmology biosimilar in the US. The product joins Harrow's expanding retina franchise, which includes IHEEZO and TRIESENCE. The company aims to strengthen its position in the estimated $9 billion US anti-VEGF market, providing retina specialists with buy-and-bill products for treating sight-threatening retinal diseases.
Harrow has re-launched VERKAZIA (cyclosporine ophthalmic emulsion) 0.1%, a prescription therapy for vernal keratoconjunctivitis (VKC), a serious allergic eye disease primarily affecting children. The re-launch includes a comprehensive commercial strategy focused on physician education, patient access and affordability initiatives. VERKAZIA is a calcineurin inhibitor immunomodulator that targets VKC's underlying inflammatory mechanisms and may reduce the need for steroid rescue, which carries risks including glaucoma or cataract formation. VKC can lead to sight-threatening conditions if left untreated. Chief Executive Officer Mark Baum said the re-launch aims to ensure dependable supply and remove access barriers for this evidence-based, steroid-sparing treatment. VERKAZIA represents the second of three priority products in Harrow's portfolio currently being executed.
Harrow, Inc. (NASDAQ:HROW) had its price target reduced to $60 from $65 by B.Riley on 14 May, though the firm maintained its Buy rating. The adjustment followed first-quarter results impacted by weaker pricing for VEVYE and lowered near-term growth expectations. The Nashville-based ophthalmic pharmaceutical company reported first-quarter revenue of $44.2 million, including an $8 million non-recurring adjustment related to VEVYE commercial coverage. Despite pricing pressures, the company highlighted record VEVYE prescriptions and strong performance from IHEEZO and TRIESENCE, with unit demand rising 18% and doubling respectively year over year. Harrow reaffirmed full-year revenue guidance of $350–$365 million. B.Riley cited upcoming product launches, reimbursement coding catalysts and expanding commercial leverage as factors supporting stronger second-half performance.